The estimated Net Worth of Carlos V Paya is at least $448 Mille dollars as of 23 March 2021. Carlos Paya owns over 2,500 units of Mallinckrodt Plc stock worth over $20,132 and over the last 9 years he sold MNK stock worth over $74,876. In addition, he makes $352,805 as Independent Director at Mallinckrodt Plc.
Carlos has made over 10 trades of the Mallinckrodt Plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 2,500 units of MNK stock worth $850 on 23 March 2021.
The largest trade he's ever made was selling 13,014 units of Mallinckrodt Plc stock on 3 January 2019 worth over $20,562. On average, Carlos trades about 1,620 units every 50 days since 2015. As of 23 March 2021 he still owns at least 59,212 units of Mallinckrodt Plc stock.
You can see the complete history of Carlos Paya stock trades at the bottom of the page.
Dr. Carlos V. Paya M.D. Ph.D. is Independent Director of the Company. Dr. Paya recently stepped down as the president, chief executive officer and board member of Immune Design Corp., a late-stage immunotherapy company, following its acquisition by Merck. He previously served as president of Elan Pharmaceuticals, and spent a number of years with Eli Lilly and Co. in discovery research, clinical development leadership roles, most recently global leader of the diabetes and endocrine franchise. Prior to his industry roles, Dr. Paya spent nearly a decade at the Mayo Clinic-Rochester, including his role as professor of medicine, immunology and pathology, and vice dean of the clinical investigation program. He is also a member of the board of BIO (Biotechnology Innovation Organization), and a board member and chair of the nominating and governance committee for Fludigm Corporation, a biotechnology tools provider.
As the Independent Director of Mallinckrodt Plc, the total compensation of Carlos Paya at Mallinckrodt Plc is $352,805. There are 13 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
Carlos Paya is 61, he's been the Independent Director of Mallinckrodt Plc since 2019. There are 5 older and 8 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
Carlos's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... e Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: